Eli Lilly and Co (LLY)
776.75
-4.35
(-0.56%)
USD |
NYSE |
May 01, 16:00
777.12
+0.37
(+0.05%)
After-Hours: 20:00
Eli Lilly Revenue (TTM): 35.93B for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 35.93B |
December 31, 2023 | 34.12B |
September 30, 2023 | 32.07B |
June 30, 2023 | 29.52B |
March 31, 2023 | 27.69B |
December 31, 2022 | 28.54B |
September 30, 2022 | 29.24B |
June 30, 2022 | 29.07B |
March 31, 2022 | 29.32B |
December 31, 2021 | 28.32B |
September 30, 2021 | 27.76B |
June 30, 2021 | 26.73B |
March 31, 2021 | 25.49B |
December 31, 2020 | 24.54B |
September 30, 2020 | 23.21B |
June 30, 2020 | 22.95B |
March 31, 2020 | 23.09B |
December 31, 2019 | 22.32B |
September 30, 2019 | 21.84B |
June 30, 2019 | 21.67B |
March 31, 2019 | 21.62B |
December 31, 2018 | 21.49B |
September 30, 2018 | 19.12B |
June 30, 2018 | 19.47B |
March 31, 2018 | 19.71B |
Date | Value |
---|---|
December 31, 2017 | 19.97B |
September 30, 2017 | 22.47B |
June 30, 2017 | 22.00B |
March 31, 2017 | 21.59B |
December 31, 2016 | 21.22B |
September 30, 2016 | 20.84B |
June 30, 2016 | 20.61B |
March 31, 2016 | 20.18B |
December 31, 2015 | 19.96B |
September 30, 2015 | 19.70B |
June 30, 2015 | 19.62B |
March 31, 2015 | 19.58B |
December 31, 2014 | 19.62B |
September 30, 2014 | 20.30B |
June 30, 2014 | 21.20B |
March 31, 2014 | 22.19B |
December 31, 2013 | 23.11B |
September 30, 2013 | 23.26B |
June 30, 2013 | 22.93B |
March 31, 2013 | 22.60B |
December 31, 2012 | 22.60B |
September 30, 2012 | 22.69B |
June 30, 2012 | 23.40B |
March 31, 2012 | 24.05B |
December 31, 2011 | 24.29B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
21.67B
Minimum
Jun 2019
35.93B
Maximum
Mar 2024
27.17B
Average
27.72B
Median
Revenue (TTM) Benchmarks
Amgen Inc | 28.19B |
Madrigal Pharmaceuticals Inc | -- |
Vertex Pharmaceuticals Inc | 9.869B |
Viking Therapeutics Inc | -- |
Moderna Inc | 6.754B |